Tags

Type your tag names separated by a space and hit enter

A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg.
Rheumatology (Oxford). 2008 Feb; 47(2):208-11.R

Abstract

OBJECTIVES

The aetiopathogenesis of the fibromyalgia syndrome (FMS) remains unknown. Recent reports, however, suggest that a subgroup of FMS subjects has an immune-mediated disease. Therefore, our primary objective was to study FMS subjects for evidence of an immune-mediated demyelinating polyneuropathy. Our secondary objective was to determine the effects of treating these FMS subjects with the immune modulator, intravenous immunoglobulin (IVIg).

METHODS

Fifty-eight FMS subjects, 26 rheumatic non-FMS subjects and 52 non-rheumatic non-FMS subjects were studied. Subjective measures of paraesthesias, weakness, stocking hypaesthesia, pain, fatigue and stiffness were made. Objective measures of tenderness, proximal muscle strength and electrodiagnostic (EDX) evidence of polyneuropathy and demyelination were also made. Eleven other FMS subjects underwent sural nerve biopsy.

RESULTS

Paraesthesias, subjective weakness and stocking hypaesthesia were more common in FMS than in rheumatic non-FMS (P < or = 0.0001). Proximal muscle strength was less in FMS than in rheumatic non-FMS (P < or = 0.0001). EDX demonstrated a distal demyelinating polyneuropathy, suggestive of chronic inflammatory demyelinating polyneuropathy (CIDP), in 33% of FMS subjects. No rheumatic non-FMS subject had polyneuropathy (P = 0.005), or demyelination (P = 0.05). Fifteen FMS/CIDP subjects were subsequently treated with IVIg (400 mg/kg each day for 5 days). Pain (P = 0.01), tenderness (P = 0.001) and strength (P = 0.04) improved significantly. Fatigue and stiffness trended towards improvement.

CONCLUSIONS

A significant subset of FMS subjects have clinical and EDX findings suggestive of CIDP. IVIg treatment shows promise in treating this subset. These observations have implications for better understanding and treating some FMS patients.

Authors+Show Affiliations

Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. xjcaro@earthlink.netNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18208823

Citation

Caro, X J., et al. "A Subset of Fibromyalgia Patients Have Findings Suggestive of Chronic Inflammatory Demyelinating Polyneuropathy and Appear to Respond to IVIg." Rheumatology (Oxford, England), vol. 47, no. 2, 2008, pp. 208-11.
Caro XJ, Winter EF, Dumas AJ. A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. Rheumatology (Oxford). 2008;47(2):208-11.
Caro, X. J., Winter, E. F., & Dumas, A. J. (2008). A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. Rheumatology (Oxford, England), 47(2), 208-11. https://doi.org/10.1093/rheumatology/kem345
Caro XJ, Winter EF, Dumas AJ. A Subset of Fibromyalgia Patients Have Findings Suggestive of Chronic Inflammatory Demyelinating Polyneuropathy and Appear to Respond to IVIg. Rheumatology (Oxford). 2008;47(2):208-11. PubMed PMID: 18208823.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. AU - Caro,X J, AU - Winter,E F, AU - Dumas,A J, PY - 2008/1/23/pubmed PY - 2008/3/6/medline PY - 2008/1/23/entrez SP - 208 EP - 11 JF - Rheumatology (Oxford, England) JO - Rheumatology (Oxford) VL - 47 IS - 2 N2 - OBJECTIVES: The aetiopathogenesis of the fibromyalgia syndrome (FMS) remains unknown. Recent reports, however, suggest that a subgroup of FMS subjects has an immune-mediated disease. Therefore, our primary objective was to study FMS subjects for evidence of an immune-mediated demyelinating polyneuropathy. Our secondary objective was to determine the effects of treating these FMS subjects with the immune modulator, intravenous immunoglobulin (IVIg). METHODS: Fifty-eight FMS subjects, 26 rheumatic non-FMS subjects and 52 non-rheumatic non-FMS subjects were studied. Subjective measures of paraesthesias, weakness, stocking hypaesthesia, pain, fatigue and stiffness were made. Objective measures of tenderness, proximal muscle strength and electrodiagnostic (EDX) evidence of polyneuropathy and demyelination were also made. Eleven other FMS subjects underwent sural nerve biopsy. RESULTS: Paraesthesias, subjective weakness and stocking hypaesthesia were more common in FMS than in rheumatic non-FMS (P < or = 0.0001). Proximal muscle strength was less in FMS than in rheumatic non-FMS (P < or = 0.0001). EDX demonstrated a distal demyelinating polyneuropathy, suggestive of chronic inflammatory demyelinating polyneuropathy (CIDP), in 33% of FMS subjects. No rheumatic non-FMS subject had polyneuropathy (P = 0.005), or demyelination (P = 0.05). Fifteen FMS/CIDP subjects were subsequently treated with IVIg (400 mg/kg each day for 5 days). Pain (P = 0.01), tenderness (P = 0.001) and strength (P = 0.04) improved significantly. Fatigue and stiffness trended towards improvement. CONCLUSIONS: A significant subset of FMS subjects have clinical and EDX findings suggestive of CIDP. IVIg treatment shows promise in treating this subset. These observations have implications for better understanding and treating some FMS patients. SN - 1462-0332 UR - https://www.unboundmedicine.com/medline/citation/18208823/A_subset_of_fibromyalgia_patients_have_findings_suggestive_of_chronic_inflammatory_demyelinating_polyneuropathy_and_appear_to_respond_to_IVIg_ L2 - https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kem345 DB - PRIME DP - Unbound Medicine ER -